19-Nov-2026 11:12:23

BETAGeneral news

BETA DRUGS: FORMS $8.7 MN ONCOLOGY JV IN ALGERIA; TO INVEST $3 MN OVER 3 YEARS

• Strategic JV: Signed Joint Venture Agreement with Algeria-based IMGSA Groupe SPA to manufacture and market oncology pharmaceutical products • Investment Size: Total JV investment of approximately $8.7 Mn, including manufacturing infrastructure and technology transfer • Beta Investment: Plans to invest $3 Mn over 3 years, along with technology transfer valued at $1.26 Mn • IMGSA Contribution: Will contribute approximately $4.43 Mn through transfer of an existing oncology manufacturing plant and machinery • Ownership Structure: Beta Drugs will hold 49% stake, while IMGSA will own 51%, in line with Algeria's pharmaceutical sector regulations • Management Control: Despite holding 49%, Beta will manage day-to-day operations and have majority representation on the JV Board • Manufacturing Expansion: JV will acquire IMGSA's existing oncology facility equipped with injectable and oral solid dosage manufacturing lines • Existing Business: Beta Drugs has supplied oncology formulations to IMGSA for the past 4 years, providing an established commercial relationship • Export Opportunities: Partnership provides access to Algeria's pharmaceutical market, with potential expansion opportunities across North Africa • Regulatory Status: Transaction remains subject to customary closing formalities and applicable local regulations

BETA DRUGS LIMITED

← Back to feed